Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom

Case Series

Emily J. Culme-Seymour, Katrina Mason, Laura Vallejo-Torres, Carla Carvalho, Leanne Partington, Claire Crowley, Nick J. Hamilton, Ed C. Toll, Colin R. Butler, Martin J. Elliott, Martin A. Birchall, Mark W. Lowdell, Chris Mason

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Stem cell-based tissue-engineered tracheas are at an early stage in their product development cycle. Tens of patients have been treated worldwide in predominantly compassionate use settings, demonstrating significant promise. This potentially life-saving treatment is complex, and the cost and its implications for such treatments are yet to be fully understood. The costs are compounded by varying strategies for graft preparation and transplant, resulting in differing clinical and laboratory costs from different research groups. In this study, we present a detailed breakdown of the clinical and manufacturing costs for three of the United Kingdom (UK) patients treated with such transplants. All three patients were treated under Compassionate Use legislation, within the UK National Health Service (NHS) hospital setting. The total costs for the three UK patients treated ranged from $174,420 to $740,500. All three patients were in a state of poor health at time of treatment and had a number of complexities in addition to the restricted airway. This is the first time a cost analysis has been made for a tissue-engineered organ and provides a benchmark for future studies, as well as comparative data for use in reimbursement considerations.

Original languageEnglish (US)
Pages (from-to)208-213
Number of pages6
JournalTissue Engineering - Part A
Volume22
Issue number3-4
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Transplants
Stem cells
Stem Cells
Tissue
Costs and Cost Analysis
Compassionate Use Trials
Costs
Health
Benchmarking
National Health Programs
Trachea
Legislation
Grafts
Product development
United Kingdom
Therapeutics
Research

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials

Cite this

Culme-Seymour, E. J., Mason, K., Vallejo-Torres, L., Carvalho, C., Partington, L., Crowley, C., ... Mason, C. (2016). Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom: Case Series. Tissue Engineering - Part A, 22(3-4), 208-213. https://doi.org/10.1089/ten.tea.2015.0283

Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom : Case Series. / Culme-Seymour, Emily J.; Mason, Katrina; Vallejo-Torres, Laura; Carvalho, Carla; Partington, Leanne; Crowley, Claire; Hamilton, Nick J.; Toll, Ed C.; Butler, Colin R.; Elliott, Martin J.; Birchall, Martin A.; Lowdell, Mark W.; Mason, Chris.

In: Tissue Engineering - Part A, Vol. 22, No. 3-4, 01.02.2016, p. 208-213.

Research output: Contribution to journalArticle

Culme-Seymour, EJ, Mason, K, Vallejo-Torres, L, Carvalho, C, Partington, L, Crowley, C, Hamilton, NJ, Toll, EC, Butler, CR, Elliott, MJ, Birchall, MA, Lowdell, MW & Mason, C 2016, 'Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom: Case Series', Tissue Engineering - Part A, vol. 22, no. 3-4, pp. 208-213. https://doi.org/10.1089/ten.tea.2015.0283
Culme-Seymour EJ, Mason K, Vallejo-Torres L, Carvalho C, Partington L, Crowley C et al. Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom: Case Series. Tissue Engineering - Part A. 2016 Feb 1;22(3-4):208-213. https://doi.org/10.1089/ten.tea.2015.0283
Culme-Seymour, Emily J. ; Mason, Katrina ; Vallejo-Torres, Laura ; Carvalho, Carla ; Partington, Leanne ; Crowley, Claire ; Hamilton, Nick J. ; Toll, Ed C. ; Butler, Colin R. ; Elliott, Martin J. ; Birchall, Martin A. ; Lowdell, Mark W. ; Mason, Chris. / Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom : Case Series. In: Tissue Engineering - Part A. 2016 ; Vol. 22, No. 3-4. pp. 208-213.
@article{5bfab0cbcd0040a4b68ea3621ea0364b,
title = "Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom: Case Series",
abstract = "Stem cell-based tissue-engineered tracheas are at an early stage in their product development cycle. Tens of patients have been treated worldwide in predominantly compassionate use settings, demonstrating significant promise. This potentially life-saving treatment is complex, and the cost and its implications for such treatments are yet to be fully understood. The costs are compounded by varying strategies for graft preparation and transplant, resulting in differing clinical and laboratory costs from different research groups. In this study, we present a detailed breakdown of the clinical and manufacturing costs for three of the United Kingdom (UK) patients treated with such transplants. All three patients were treated under Compassionate Use legislation, within the UK National Health Service (NHS) hospital setting. The total costs for the three UK patients treated ranged from $174,420 to $740,500. All three patients were in a state of poor health at time of treatment and had a number of complexities in addition to the restricted airway. This is the first time a cost analysis has been made for a tissue-engineered organ and provides a benchmark for future studies, as well as comparative data for use in reimbursement considerations.",
author = "Culme-Seymour, {Emily J.} and Katrina Mason and Laura Vallejo-Torres and Carla Carvalho and Leanne Partington and Claire Crowley and Hamilton, {Nick J.} and Toll, {Ed C.} and Butler, {Colin R.} and Elliott, {Martin J.} and Birchall, {Martin A.} and Lowdell, {Mark W.} and Chris Mason",
year = "2016",
month = "2",
day = "1",
doi = "10.1089/ten.tea.2015.0283",
language = "English (US)",
volume = "22",
pages = "208--213",
journal = "Tissue Engineering - Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "3-4",

}

TY - JOUR

T1 - Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom

T2 - Case Series

AU - Culme-Seymour, Emily J.

AU - Mason, Katrina

AU - Vallejo-Torres, Laura

AU - Carvalho, Carla

AU - Partington, Leanne

AU - Crowley, Claire

AU - Hamilton, Nick J.

AU - Toll, Ed C.

AU - Butler, Colin R.

AU - Elliott, Martin J.

AU - Birchall, Martin A.

AU - Lowdell, Mark W.

AU - Mason, Chris

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Stem cell-based tissue-engineered tracheas are at an early stage in their product development cycle. Tens of patients have been treated worldwide in predominantly compassionate use settings, demonstrating significant promise. This potentially life-saving treatment is complex, and the cost and its implications for such treatments are yet to be fully understood. The costs are compounded by varying strategies for graft preparation and transplant, resulting in differing clinical and laboratory costs from different research groups. In this study, we present a detailed breakdown of the clinical and manufacturing costs for three of the United Kingdom (UK) patients treated with such transplants. All three patients were treated under Compassionate Use legislation, within the UK National Health Service (NHS) hospital setting. The total costs for the three UK patients treated ranged from $174,420 to $740,500. All three patients were in a state of poor health at time of treatment and had a number of complexities in addition to the restricted airway. This is the first time a cost analysis has been made for a tissue-engineered organ and provides a benchmark for future studies, as well as comparative data for use in reimbursement considerations.

AB - Stem cell-based tissue-engineered tracheas are at an early stage in their product development cycle. Tens of patients have been treated worldwide in predominantly compassionate use settings, demonstrating significant promise. This potentially life-saving treatment is complex, and the cost and its implications for such treatments are yet to be fully understood. The costs are compounded by varying strategies for graft preparation and transplant, resulting in differing clinical and laboratory costs from different research groups. In this study, we present a detailed breakdown of the clinical and manufacturing costs for three of the United Kingdom (UK) patients treated with such transplants. All three patients were treated under Compassionate Use legislation, within the UK National Health Service (NHS) hospital setting. The total costs for the three UK patients treated ranged from $174,420 to $740,500. All three patients were in a state of poor health at time of treatment and had a number of complexities in addition to the restricted airway. This is the first time a cost analysis has been made for a tissue-engineered organ and provides a benchmark for future studies, as well as comparative data for use in reimbursement considerations.

UR - http://www.scopus.com/inward/record.url?scp=84959059163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959059163&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2015.0283

DO - 10.1089/ten.tea.2015.0283

M3 - Article

VL - 22

SP - 208

EP - 213

JO - Tissue Engineering - Part A

JF - Tissue Engineering - Part A

SN - 1937-3341

IS - 3-4

ER -